<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "6: early stage", fill: "#f984e5"},
{source: "6: early stage", target: "6: development", fill: "#f984e5"},
{source: "6: early stage", target: "7: potential drug delivery products", fill: "#f28500"},
{source: "7: potential drug delivery products", target: "7: research development", fill: "#f28500"},
{source: "7: potential drug delivery products", target: "9: cannot assure", fill: "#6b8e23"},
{source: "9: cannot assure", target: "9: development", fill: "#6b8e23"},
{source: "9: development", target: "9: efforts will", fill: "#6b8e23"},
{source: "9: efforts will", target: "9: potential products will", fill: "#6b8e23"},
{source: "9: potential products will", target: "9: effective", fill: "#6b8e23"},
{source: "9: effective", target: "9: regulatory clearance", fill: "#6b8e23"},
{source: "9: cannot assure", target: "10: potential products", fill: "#ecd540"},
{source: "10: potential products", target: "10: manufactured", fill: "#ecd540"},
{source: "10: manufactured", target: "10: commercial quantities", fill: "#ecd540"},
{source: "10: commercial quantities", target: "10: marketed successfully", fill: "#ecd540"},
{source: "10: potential products", target: "11: feasibility", fill: "#b39eb5"},
{source: "11: feasibility", target: "11: demonstrate", fill: "#b39eb5"},
{source: "11: demonstrate", target: "11: regulatory", fill: "#b39eb5"},
{source: "11: regulatory", target: "11: successfully", fill: "#b39eb5"},
{source: "11: successfully", target: "11: negatively", fill: "#b39eb5"},
{source: "11: feasibility", target: "16: conduct costly", fill: "#e9d66b"},
{source: "16: conduct costly", target: "16: timeconsuming research", fill: "#e9d66b"},
{source: "16: timeconsuming research", target: "16: commercialize", fill: "#e9d66b"},
{source: "16: commercialize", target: "16: technology", fill: "#e9d66b"},
{source: "16: conduct costly", target: "17: future capital requirements will depend on", fill: "#967bb6"},
{source: "17: future capital requirements will depend on", target: "17: researching", fill: "#967bb6"},
{source: "17: researching", target: "17: technology", fill: "#967bb6"},
{source: "17: technology", target: "17: delivery systems", fill: "#967bb6"},
{source: "17: delivery systems", target: "17: potential applications", fill: "#967bb6"},
{source: "17: potential applications", target: "17: collaborative", fill: "#967bb6"},
{source: "17: collaborative", target: "17: arrangements with others", fill: "#967bb6"},
{source: "17: arrangements with others", target: "17: with preclinical studies", fill: "#967bb6"},
{source: "17: with preclinical studies", target: "17: clinical trials", fill: "#967bb6"},
{source: "17: clinical trials", target: "17: regulatory approvals", fill: "#967bb6"},
{source: "17: regulatory approvals", target: "17: development", fill: "#967bb6"},
{source: "17: development", target: "17: rate at which", fill: "#967bb6"},
{source: "17: rate at which", target: "17: technologies", fill: "#967bb6"},
{source: "17: technologies", target: "17: filing prosecuting", fill: "#967bb6"},
{source: "17: future capital requirements will depend on", target: "22: through public", fill: "#fff"},
{source: "22: through public", target: "22: private equity financing although additional equity", fill: "#fff"},
{source: "22: private equity financing although additional equity", target: "22: financing will", fill: "#fff"},
{source: "22: financing will", target: "22: shareholders equity deficit", fill: "#fff"},
{source: "22: through public", target: "29: losses over at least", fill: "#c19a6b"},
{source: "29: losses over at least", target: "29: several years as", fill: "#c19a6b"},
{source: "29: several years as", target: "29: development efforts", fill: "#c19a6b"},
{source: "29: development efforts", target: "29: clinical testing activities", fill: "#c19a6b"},
{source: "29: clinical testing activities", target: "29: pursue additional applications", fill: "#c19a6b"},
{source: "29: pursue additional applications", target: "29: existing delivery platforms", fill: "#c19a6b"},
{source: "29: existing delivery platforms", target: "29: manufacturing efforts", fill: "#c19a6b"},
{source: "29: manufacturing efforts", target: "29: commercial production capabilities", fill: "#c19a6b"},
{source: "29: losses over at least", target: "30: sustain profitability", fill: "#ffe4c4"},
{source: "30: sustain profitability", target: "30: with others", fill: "#ffe4c4"},
{source: "30: with others", target: "30: regulatory approval", fill: "#ffe4c4"},
{source: "30: regulatory approval", target: "30: manufacture market", fill: "#ffe4c4"},
{source: "30: manufacture market", target: "30: products using", fill: "#ffe4c4"},
{source: "30: products using", target: "30: drug delivery platforms", fill: "#ffe4c4"},
{source: "30: sustain profitability", target: "36: cannot assure", fill: "#32cd32"},
{source: "36: cannot assure", target: "36: addressing", fill: "#32cd32"},
{source: "36: addressing", target: "36: engineering", fill: "#32cd32"},
{source: "36: engineering", target: "36: manufacturing", fill: "#32cd32"},
{source: "36: cannot assure", target: "39: delivery technologies", fill: "#cf0"},
{source: "39: delivery technologies", target: "39: commercially", fill: "#cf0"},
{source: "39: commercially", target: "39: cannot assure", fill: "#cf0"},
{source: "39: cannot assure", target: "39: such applications will", fill: "#cf0"},
{source: "39: delivery technologies", target: "43: potential products", fill: "#c89"},
{source: "43: potential products", target: "43: timely manner", fill: "#c89"},
{source: "43: potential products", target: "85: application", fill: "#3cb371"},
{source: "85: application", target: "85: Intraject ", fill: "#3cb371"},
{source: "85: Intraject ", target: "85: secure such", fill: "#3cb371"},
{source: "85: application", target: "START_HERE", fill: "#3cb371"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Construction and Engineering</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Pharmaceuticals</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Policy</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Natural disaster</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Drug_delivery">Drug delivery</a></td>
      <td>Drug delivery refers to approaches, formulations, manufacturing techniques, storage systems, and technologies involved in transporting a pharmaceutical compound to its target site to achieve a desired therapeutic effect. Principles related to drug preparation, route of administration, site-specific targeting, metabolism, and toxicity are used to optimize efficacy and safety, and to improve patient convenience and compliance.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Delivery_drone">Delivery drone</a></td>
      <td>A delivery drone is an unmanned aerial vehicle (UAV) used to transport packages, medical supplies, food, or other goods. Delivery drones are typically autonomous.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Alisher_Usmanov">Alisher Usmanov</a></td>
      <td>Alisher Burkhanovich Usmanov (Russian: Алишер Бурханович Усманов; born 9 September 1953) is an Uzbek-born Russian businessman and oligarch. By 2022, Usmanov had an estimated net worth of $19.5 billion and was among the world's 100 wealthiest people.Usmanov made his wealth after the collapse of the Soviet Union, through metal and mining operations, and investments.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Hardware_random_number_generator">Hardware random number generator</a></td>
      <td>In computing, a hardware random number generator (HRNG) or true random number generator (TRNG) is a device that generates random numbers from a physical process, rather than by means of an algorithm.  Such devices are often based on microscopic phenomena that generate low-level, statistically random "noise" signals, such as thermal noise, the photoelectric effect, involving a beam splitter, and other quantum phenomena.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/William_Murphy_(musician)">William Murphy (musician)</a></td>
      <td>William Henry Murphy III (born August 2, 1973) is an American gospel recording artist and pastor. He started his music career in 2005, with the release of All Day on Epic Records.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Statement_of_Demonstrated_Ability">Statement of Demonstrated Ability</a></td>
      <td>A Statement of Demonstrated Ability is a statement granted at the discretion of a Federal Air Surgeon to a person who is disqualified from obtaining a pilot's medical certification. It is granted only if the disqualifying condition or disease is static or non-progressive, and the person has been found capable of performing airman duties without endangering public safety.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Fact">Fact</a></td>
      <td>A fact is something that is true. The usual test for a statement of fact is verifiability, that is whether it can be demonstrated to correspond to experience.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_agency">Regulatory agency</a></td>
      <td>A regulatory agency (regulatory body, regulator) or independent agency (independent regulatory agency) is a government authority that is responsible for exercising autonomous dominion over some area of human activity in a licensing and regulating capacity.\nThese are customarily set up to strengthen safety and standards, and/or to protect consumers in markets where there is a lack of effective competition.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_state">Regulatory state</a></td>
      <td>The term regulatory state refers to the expansion in the use of rulemaking, monitoring and enforcement techniques and institutions by the state and to a parallel change in the way its positive or negative functions in society are being carried out. The expansion of the state nowadays is generally via regulation and less via taxing and spending.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_affairs">Regulatory affairs</a></td>
      <td>Regulatory affairs (RA), also called government affairs, is a profession within regulated industries, such as pharmaceuticals, medical devices, cosmetics, agrochemicals (plant protection products and fertilizers), energy, banking, telecom etc.  Regulatory affairs also has a very specific meaning within the healthcare industries (pharmaceuticals, medical devices, biologics and functional foods).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_sign">Regulatory sign</a></td>
      <td>A regulatory sign is used to indicate or reinforce traffic laws, regulations or requirements which apply either at all times or at specified times or places upon a street or highway, the disregard of which may constitute a violation, or a sign in general that regulates public behavior in places open to the public.  The FHWA defines regulatory sign as "a sign that gives notice to road users of traffic laws or regulations".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Cis-regulatory_element">Cis-regulatory element</a></td>
      <td>Cis-regulatory elements (CREs) or Cis-regulatory modules (CRMs) are regions of non-coding DNA which regulate the transcription of neighboring genes. CREs are vital components of genetic regulatory networks, which in turn control morphogenesis, the development of anatomy, and other aspects of embryonic development, studied in evolutionary developmental biology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_use_of_space">Commercial use of space</a></td>
      <td>Commercial use of space is the provision of goods or services of commercial value by using equipment sent into Earth orbit or outer space.  This phenomenon – aka Space Economy (or New Space Economy) – is accelerating cross-sector innovation processes combining the most advanced space and digital technologies to develop a broad portfolio of space-based services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_software">Commercial software</a></td>
      <td>Commercial software, or seldom payware, is a computer software that is produced for sale or that serves commercial purposes. Commercial software can be proprietary software or free and open-source software.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renewable_energy_commercialization">Renewable energy commercialization</a></td>
      <td>Renewable energy commercialization involves the deployment of three generations of renewable energy technologies dating back more than 100 years. First-generation technologies, which are already mature and economically competitive, include biomass, hydroelectricity, geothermal power and heat.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization_of_love">Commercialization of love</a></td>
      <td>The notion of commercialization of love, that is not to be confused with prostitution (the commercialization of sexual activity), involves the definitions of romantic love and consumerism.\n\n\n== Sociological development ==\nThe commercialization of love is the ongoing process of infiltration of commercial and economical stimuli in the daily life of lovers and the association of monetary and non-monetary symbols and commodities in the love relationships.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Electronic_cigarette">Electronic cigarette</a></td>
      <td>An electronic cigarette is an electronic device that simulates tobacco smoking.  It consists of an atomizer, a power source such as a battery, and a container such as a cartridge or tank.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phases_of_clinical_research">Phases of clinical research</a></td>
      <td>The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases start with testing for safety in a few human subjects, then expand to many study participants (potentially tens of thousands) to determine if the treatment is effective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trial">Clinical trial</a></td>
      <td>Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Randomized_controlled_trial">Randomized controlled trial</a></td>
      <td>A randomized controlled trial (or randomized control trial; RCT) is a form of scientific experiment used to control factors not under direct experimental control. Examples of RCTs are clinical trials that compare the effects of drugs, surgical techniques, medical devices, diagnostic procedures or other medical treatments.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Food_and_Drug_Administration">Food and Drug Administration</a></td>
      <td>The United States Food and Drug Administration (FDA or USFDA) is a federal agency of the Department of Health and Human Services. The FDA is responsible for protecting and promoting public health through the control and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs (medications), vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices (ERED), cosmetics, animal foods &amp; feed and veterinary products.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing_engineering">Manufacturing engineering</a></td>
      <td>Manufacturing engineering is a branch of professional engineering that shares many common concepts and ideas with other fields of engineering such as mechanical, chemical, electrical, and industrial engineering. \nManufacturing engineering requires the ability to plan the practices of manufacturing; to research and to develop tools, processes, machines and equipment; and to integrate the facilities and systems for producing quality products with the optimum expenditure of capital.The manufacturing or production engineer's primary focus is to turn raw material into an updated or new product in the most effective, efficient &amp; economic way possible.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Application_software">Application software</a></td>
      <td>An application program (application or app for short) is a computer program designed to carry out a specific task other than one relating to the operation of the computer itself, typically to be used by end-users. Word processors, media players, and accounting software are examples of.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Hart_Memorial_Trophy">Hart Memorial Trophy</a></td>
      <td>The Hart Memorial Trophy, originally known as the Hart Trophy is an annual award for the most valuable player to his team in the National Hockey League (NHL), voted by the members of the Professional Hockey Writers' Association. The original trophy was donated to the league in 1923 by David Hart, the father of Cecil Hart, the longtime head coach of the Montreal Canadiens.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Taylor_Hawkins">Taylor Hawkins</a></td>
      <td>Oliver Taylor Hawkins (February 17, 1972 – March 25, 2022) was an American musician, best known as the drummer of the rock band Foo Fighters, with whom he recorded nine studio albums between 1999 and 2021. Before joining the band in 1997, he was the touring drummer for Sass Jordan and for Alanis Morissette, as well as the drummer in the progressive experimental band Sylvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Interrupt">Interrupt</a></td>
      <td>In digital computers, an interrupt (sometimes referred to as a trap) is a request for the processor to interrupt currently executing code (when permitted), so that the event can be processed in a timely manner. If the request is accepted, the processor will suspend its current activities, save its state, and execute a function called an interrupt handler (or an interrupt service routine, ISR) to deal with the event.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Extract,_load,_transform">Extract, load, transform</a></td>
      <td>In computing, extract, transform, load (ETL) is a three-phase process where data is first extracted then transformed (cleaned, sanitized, scrubbed) and finally loaded into an output data container. The data can be collated from one or more sources and it can also be outputted to one or more destinations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Application_security">Application security</a></td>
      <td>Application security (short AppSec) includes all tasks that introduce a secure software development life cycle to development teams. Its final goal is to improve security practices and, through that, to find, fix and preferably prevent security issues within applications.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>ARADIGM CORP      Item 1A Risk Factors             Except for historical information contained herein, the discussion in     this Report on Form 10-K contains forward-looking statements, including,     without <font color="blue">limitation</font>, statements regarding timing and results of clinical     trials,  the  <font color="blue">establishment</font>  of <font color="blue">corporate partnering arrangements</font>, the     anticipated <font color="blue">commercial introduction</font> of our products and the timing of our     <font color="blue">cash <font color="blue">requirements</font></font></td>
    </tr>
    <tr>
      <td>These forward-looking statements involve certain risks     and <font color="blue">uncertainties</font> that could cause actual results to <font color="blue">differ materially from</font>     those in such forward-looking statements</td>
    </tr>
    <tr>
      <td><font color="blue">Potential </font>risks and <font color="blue">uncertainties</font>     include,  without  <font color="blue">limitation</font>,  those  mentioned in this report and in     particular the <font color="blue">factors described</font> below</td>
    </tr>
    <tr>
      <td>You <font color="blue">must evaluate us</font> in light of the <font color="blue">uncertainties</font> and <font color="blue">complexities</font>     present in an early-stage company</td>
    </tr>
    <tr>
      <td>All of our <font color="blue">potential products</font> are in an     <font color="blue">early stage</font> of research or <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">potential drug delivery products</font>     require  extensive research, <font color="blue">development</font> and pre-clinical and clinical     testing</td>
    </tr>
    <tr>
      <td>Because none of our products has yet received     approval by the FDA, we <font color="blue">cannot assure</font> you that our research and <font color="blue">development</font>     <font color="blue">efforts will</font> be successful, any of our <font color="blue"><font color="blue">potential products</font> will</font> be proven     safe and <font color="blue">effective</font> or <font color="blue"><font color="blue">regulatory</font> clearance</font> or approval to sell any of our     <font color="blue"><font color="blue">potential products</font> will</font> be obtained</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that any of our     <font color="blue">potential products</font> can be <font color="blue"><font color="blue">manufacture</font>d</font> in <font color="blue">commercial quantities</font> or at an     acceptable cost or <font color="blue">marketed <font color="blue">successfully</font></font></td>
    </tr>
    <tr>
      <td>Failure to achieve commercial     <font color="blue">feasibility</font>,  <font color="blue">demonstrate</font>  safety,  achieve  <font color="blue">clinical efficacy</font>, obtain     <font color="blue">regulatory</font> approval or <font color="blue">successfully</font> market <font color="blue">products will</font> <font color="blue">negatively</font> impact     our business</td>
    </tr>
    <tr>
      <td>We will need <font color="blue"><font color="blue">additional</font> capital</font> and our ability to <font color="blue">find <font color="blue">additional</font> funding</font>     is uncertain</td>
    </tr>
    <tr>
      <td>Our <font color="blue">operations</font> to date have consumed substantial and increasing     amounts  of  cash</td>
    </tr>
    <tr>
      <td>We expect the negative cash flow from <font color="blue">operations</font> to     continue in the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>We will need to commit substantial funds     to develop our <font color="blue">technology</font> and <font color="blue">proposed products</font></td>
    </tr>
    <tr>
      <td>We will have to continue to     <font color="blue">conduct costly</font> and time-consuming research and preclinical and clinical     testing to develop, refine and <font color="blue">commercialize</font> our <font color="blue">technology</font> and proposed     products</td>
    </tr>
    <tr>
      <td>Our <font color="blue">future capital <font color="blue">requirements</font> will <font color="blue">depend on</font></font> many factors,     including:         •  progress in <font color="blue">researching</font> and developing our <font color="blue">technology</font>, our drug     <font color="blue"><font color="blue">delivery system</font>s</font> and <font color="blue">potential <font color="blue">application</font>s</font>;          •   our  ability  to establish and maintain favorable <font color="blue">collaborative</font>     <font color="blue">arrangements <font color="blue">with others</font></font>;         •  progress <font color="blue">with preclinical studies</font> and <font color="blue">clinical trials</font>;         •  time and costs to obtain <font color="blue">regulatory</font> approvals;         •  costs of <font color="blue">development</font> and the <font color="blue">rate at which</font> we expand our production     <font color="blue">technologies</font>;         •  costs of preparing, filing, prosecuting, maintaining and enforcing     patent claims; and         •  our need to acquire licenses or other rights to <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Since inception, we have financed our <font color="blue">operations</font> primarily through     <font color="blue">private placements</font> and <font color="blue">public offerings</font> of our capital stock, proceeds from     equipment lease financings, contract research funding and <font color="blue">interest earned on</font>     <font color="blue">investments</font></td>
    </tr>
    <tr>
      <td>We believe that our <font color="blue">existing cash</font> and <font color="blue">cash equivalent balances at</font>     <font color="blue">December </font>31, 2005, <font color="blue">funding commitments from</font> corporate <font color="blue">development</font> partners,     and <font color="blue">interest earned on</font> our <font color="blue">investments</font> should be sufficient to meet our     needs for at least the next 12 months</td>
    </tr>
    <tr>
      <td>However, there can be <font color="blue">no assurances</font>     that these sources of <font color="blue">funding will</font> be sufficient, that our <font color="blue">cash <font color="blue">requirements</font></font>     will not change or that <font color="blue">funding commitments from</font> our corporate <font color="blue">development</font>     <font color="blue">partners will</font> not be amended or terminated</td>
    </tr>
    <tr>
      <td>21       _________________________________________________________________    [75]Table of <font color="blue">Contents       </font>      We will need to raise <font color="blue"><font color="blue">additional</font> capital</font> to fund our <font color="blue">capital spending</font>     and <font color="blue">operations</font> before we <font color="blue">become profitable</font></td>
    </tr>
    <tr>
      <td>During 2006, we will be seeking     <font color="blue">additional</font> funding through collaborations, borrowing arrangements and/ or     <font color="blue">through public</font> or private equity financing, although <font color="blue">additional</font> equity     <font color="blue">financing will</font> be needed to avoid a <font color="blue">shareholders</font>’ equity deficit</td>
    </tr>
    <tr>
      <td>We cannot     assure you that <font color="blue"><font color="blue">additional</font> financing</font> can be obtained on acceptable terms, or     at all</td>
    </tr>
    <tr>
      <td>Dilution to <font color="blue">shareholders</font> may result if funds are raised by issuing     <font color="blue">additional</font> equity securities</td>
    </tr>
    <tr>
      <td>If <font color="blue">adequate funds</font> are not <font color="blue">available during</font> the     first half of 2006, we will be required to delay, to reduce the scope of, or     to <font color="blue">eliminate one</font> or more of our research and <font color="blue">development</font> programs, or to     obtain funds through arrangements with <font color="blue">collaborative</font> partners or other     sources  that  may  require  us to <font color="blue">relinquish rights</font> to certain of our     <font color="blue">technologies</font> or products that we would not <font color="blue">otherwise relinquish</font>, and to     <font color="blue">reduce personnel</font> related costs</td>
    </tr>
    <tr>
      <td>We have a history of losses and anticipate <font color="blue">future losses</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">never been profitable</font>, and through <font color="blue">December </font>31, 2005, we have     incurred  a <font color="blue">cumulative deficit</font> of approximately dlra274dtta8 million and our     <font color="blue">shareholders</font>’ equity is only dlra7dtta2 million</td>
    </tr>
    <tr>
      <td>We have not had any <font color="blue">product sales</font>     and do not anticipate receiving any revenue from <font color="blue">product sales</font> in 2006</td>
    </tr>
    <tr>
      <td>We     expect  to continue to incur substantial <font color="blue">losses over at least</font> the next     <font color="blue">several years as</font> we:         •  expand our research and <font color="blue">development</font> efforts;         •  expand our preclinical and <font color="blue"><font color="blue">clinical testing</font> <font color="blue">activities</font></font>;         •  pursue <font color="blue">additional</font> <font color="blue">application</font>s for our <font color="blue">existing delivery platforms</font>;         •  expand our <font color="blue"><font color="blue">manufacturing</font> efforts</font>; and         •  plan and build our <font color="blue">commercial production <font color="blue">capabilities</font></font></td>
    </tr>
    <tr>
      <td>To achieve and <font color="blue">sustain profitability</font>, we must, alone or <font color="blue">with others</font>,     develop,  obtain <font color="blue">regulatory</font> approval for, <font color="blue">manufacture</font>, market and sell     <font color="blue">products using</font> our <font color="blue">drug delivery platforms</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> investors that     we <font color="blue">will generate sufficient product</font> or <font color="blue">contract research revenue</font> to become     profitable or to <font color="blue">sustain profitability</font></td>
    </tr>
    <tr>
      <td>We may not be able to develop our products <font color="blue">successfully</font></td>
    </tr>
    <tr>
      <td>Many of our products are at an <font color="blue">early stage</font> of <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Before we     can begin to sell our <font color="blue">products <font color="blue">commercially</font></font>, we will need to invest in     substantial <font color="blue">additional</font> <font color="blue">development</font> and <font color="blue">conduct <font color="blue">clinical testing</font></font></td>
    </tr>
    <tr>
      <td>In order to     further develop many of our products, we will need to <font color="blue">address <font color="blue">engineering</font></font>     and  <font color="blue">design issues</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that we will be successful in     <font color="blue">addressing</font>   these  designs,  <font color="blue">engineering</font>  and  <font color="blue">manufacturing</font>  issues</td>
    </tr>
    <tr>
      <td>Additionally, we will need to formulate and <font color="blue">package drugs</font> for <font color="blue">delivery by</font>     our AERx and <font color="blue">Intraject </font>systems</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that we will be able to     do this <font color="blue">successfully</font></td>
    </tr>
    <tr>
      <td>Even if our delivery <font color="blue">technologies</font> have been <font color="blue">successfully</font> developed and     are <font color="blue">commercially</font> feasible for a range of large and small molecule drugs, we     <font color="blue">cannot assure</font> you that <font color="blue">such <font color="blue">application</font>s will</font> be <font color="blue">commercially</font> acceptable</td>
    </tr>
    <tr>
      <td>For  our  delivery  systems to be <font color="blue">commercially</font> viable, we will need to     <font color="blue">demonstrate</font> that drugs delivered by our systems:         •  are safe and <font color="blue">effective</font>;         •  will not be subject to physical or <font color="blue">chemical instability over</font> time and     <font color="blue">under differing storage conditions</font>; and          •   do  not <font color="blue">suffer from</font> other problems that <font color="blue">would affect commercial</font>     viability</td>
    </tr>
    <tr>
      <td>While our <font color="blue">development</font> efforts are <font color="blue">at <font color="blue">different</font> stages</font> for <font color="blue">different</font>     products,  we  <font color="blue">cannot assure</font> you that we will <font color="blue">successfully</font> develop any     products</td>
    </tr>
    <tr>
      <td>We <font color="blue">may also abandon</font> some or all of our <font color="blue">proposed products</font></td>
    </tr>
    <tr>
      <td>If we     cannot develop <font color="blue">potential products</font> in a <font color="blue">timely manner</font>, our business will be     impaired</td>
    </tr>
    <tr>
      <td>22       _________________________________________________________________    [76]Table of <font color="blue">Contents       </font>We may not be able to <font color="blue">commercialize</font> products <font color="blue">successfully</font></td>
    </tr>
    <tr>
      <td>Our success in <font color="blue">commercializing</font> our <font color="blue">products depends on</font> many factors,     including  <font color="blue"><font color="blue">acceptance</font> by health care professionals</font> and patients</td>
    </tr>
    <tr>
      <td><font color="blue">Their     </font><font color="blue">acceptance</font> of our <font color="blue"><font color="blue">products will</font> largely <font color="blue">depend on</font></font> our ability to <font color="blue">demonstrate</font>     our  products’ ability to compete with alternate <font color="blue"><font color="blue">delivery system</font>s</font> with     respect to:         •  safety;         •  efficacy         •  ease of use; and         •  price</td>
    </tr>
    <tr>
      <td>There can be no assurance that our <font color="blue">products will</font> be <font color="blue">competitive with</font>     respect to these factors or that our <font color="blue">partners will</font> be able to <font color="blue">successfully</font>     market any of them in a <font color="blue">timely manner</font></td>
    </tr>
    <tr>
      <td>We  <font color="blue">depend on</font> <font color="blue">collaborative</font> partners and need <font color="blue">additional</font> <font color="blue">collaborative</font>     partners</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">commercialization</font> strategy depends on</font> our ability to <font color="blue">enter into</font>     <font color="blue"><font color="blue">agreement</font>s</font>  with  <font color="blue">collaborative</font> partners</td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">development</font>     <font color="blue">partners could terminate</font> their <font color="blue"><font color="blue">agreement</font>s</font> and we have no assurance that we     will receive any <font color="blue">development</font> and <font color="blue">milestone payments</font></td>
    </tr>
    <tr>
      <td>If we do not receive     <font color="blue">development</font> funds or achieve <font color="blue">milestones set forth</font> in the <font color="blue"><font color="blue">agreement</font>s</font>, or if     any of our <font color="blue">development</font> partners breach or terminate their <font color="blue">agreement</font>, our     business will be impaired</td>
    </tr>
    <tr>
      <td>The <font color="blue">development</font> and <font color="blue">commercialization</font> <font color="blue">of the AERx </font>iDMS will be delayed     if <font color="blue">Novo Nordisk </font>fails to conduct these <font color="blue">activities</font> in a <font color="blue">timely manner</font> or at     all</td>
    </tr>
    <tr>
      <td>Under the terms of our current <font color="blue"><font color="blue">agreement</font>s</font> with Novo Nordisk, Novo     Nordisk and its <font color="blue">affiliates</font> assumed broad control and <font color="blue">responsibility</font> with     respect to:         •  <font color="blue">development</font> and <font color="blue">commercialization</font> <font color="blue">of the AERx </font><font color="blue">diabetes <font color="blue">management</font></font>     products; and         •  <font color="blue">management</font> and operation of the <font color="blue">manufacturing</font> <font color="blue">facility</font> for the AERx     iDMS              We will also need to <font color="blue">enter into</font> <font color="blue"><font color="blue">agreement</font>s</font> with other corporate     partners to conduct the <font color="blue">clinical trials</font>, <font color="blue">manufacturing</font>, marketing and sales     <font color="blue">necessary</font>  to  <font color="blue">commercialize</font>  other <font color="blue">potential products</font> on our AERx and     <font color="blue">Intraject </font>systems</td>
    </tr>
    <tr>
      <td>In addition, our ability to apply our <font color="blue"><font color="blue">delivery system</font>s</font> to     any <font color="blue"><font color="blue">proprietary</font> drugs will <font color="blue">depend on</font></font> our ability to establish and maintain     <font color="blue"><font color="blue">corporate partners</font>hips</font> or other <font color="blue">collaborative</font> arrangements with the holders     of <font color="blue"><font color="blue">proprietary</font> rights</font> to such drugs</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that we will be     able to establish such <font color="blue">additional</font> <font color="blue"><font color="blue">corporate partners</font>hips</font> or <font color="blue">collaborative</font>     <font color="blue">arrangements on</font> favorable terms or at all, or that our existing or future     <font color="blue"><font color="blue">corporate partners</font>hips</font> or <font color="blue">collaborative</font> arrangements will be successful</td>
    </tr>
    <tr>
      <td>We     can  not  assure you that our existing or <font color="blue">future <font color="blue">corporate partners</font></font> or     <font color="blue">collaborators</font>  will  not  pursue  <font color="blue">alternative</font>  <font color="blue">technologies</font> or develop     <font color="blue">alternative</font> products either on their own or in collaboration <font color="blue">with others</font>,     including our <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>We could have <font color="blue">disputes with</font> our existing or     <font color="blue">future <font color="blue">corporate partners</font></font> or <font color="blue">collaborators</font></td>
    </tr>
    <tr>
      <td>Any such dis<font color="blue"><font color="blue">agreement</font>s</font> could     lead to delays in the research, <font color="blue">development</font> or <font color="blue">commercialization</font> of any     potential  products  or  could  result in time-consuming and expensive     <font color="blue">litigation</font> or arbitration, which may not be resolved in our favor</td>
    </tr>
    <tr>
      <td>If any of     our <font color="blue">corporate partners</font> or <font color="blue">collaborators</font> do not develop or <font color="blue">commercialize</font> any     product to which it has obtained <font color="blue">rights from us</font>, our business could be     impaired</td>
    </tr>
    <tr>
      <td>We have limited <font color="blue">manufacturing</font> experience</td>
    </tr>
    <tr>
      <td>We have <font color="blue">validated only</font> a single clinical <font color="blue">manufacturing</font> <font color="blue">facility</font> for     our <font color="blue">single <font color="blue">dosage forms</font></font> for our AERx <font color="blue">delivery system</font>, and <font color="blue">responsibility</font> for     and control of this <font color="blue">facility</font> has transferred to NNDT We have limited future     access to the NNDT <font color="blue">manufacturing</font> <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>23       _________________________________________________________________    [77]Table of <font color="blue">Contents       </font>      Either our <font color="blue">development</font> partners or we will have to <font color="blue">invest <font color="blue">significant</font></font>     amounts to attempt to provide for the high-volume <font color="blue">manufacturing</font> required for     <font color="blue">multiple products</font>, and much of this <font color="blue">spending will</font> occur before our products     are approved</td>
    </tr>
    <tr>
      <td>There can be no assurance that:         •  the <font color="blue">design <font color="blue">requirements</font></font> of our pulmonary and <font color="blue">subcutaneous systems will</font>     make it feasible for us to develop it beyond the <font color="blue">current prototype</font>;         •  <font color="blue">manufacturing</font> and <font color="blue">quality control problems will</font> not arise as we attempt     to scale-up; or         •  any scale-up can be achieved in a <font color="blue">timely manner</font> or at a <font color="blue">commercially</font>     <font color="blue">reasonable cost</font></td>
    </tr>
    <tr>
      <td>Failure to address these issues could delay or prevent late-stage clinical     testing and <font color="blue">commercialization</font> of our products</td>
    </tr>
    <tr>
      <td>We have limited <font color="blue">capacity</font> to <font color="blue"><font color="blue">manufacture</font> <font color="blue">key <font color="blue">components</font></font></font> of our drug     <font color="blue"><font color="blue">delivery system</font>s</font></td>
    </tr>
    <tr>
      <td>Under the terms of a Contract Manufacturing Agreement we     have <font color="blue">entered into with</font> NNDT, NNDT agreed to <font color="blue">supply devices</font> and <font color="blue">dosage forms</font>     to us for <font color="blue">development</font> of our other AERx systems</td>
    </tr>
    <tr>
      <td>This <font color="blue">agreement</font> expires at     the end of 2007, and there can be no assurance that we will be able to     extend this <font color="blue">agreement</font> at satisfactory terms or that we will be able to find     a <font color="blue">replacement supplier at</font> satisfactory terms</td>
    </tr>
    <tr>
      <td>We  may  decide  to invest in <font color="blue">additional</font> clinical <font color="blue">manufacturing</font>     <font color="blue">facilities</font> in order to <font color="blue">internally</font> produce <font color="blue">critical <font color="blue">components</font></font> of our drug     <font color="blue"><font color="blue">delivery system</font>s</font> including the disposable nozzles, assemble the disposable     unit-dose packets and fill the drug into the unit-dose packets</td>
    </tr>
    <tr>
      <td>We intend to <font color="blue">use <font color="blue">contract <font color="blue">manufacture</font>rs</font></font> to produce <font color="blue">key <font color="blue">components</font></font>,     assemblies and <font color="blue">subassemblies</font> in the clinical and commercial <font color="blue">manufacturing</font> of     our <font color="blue">delivery devices</font></td>
    </tr>
    <tr>
      <td>There can be no assurance that we will be able to     <font color="blue">enter into</font> or maintain satisfactory contract <font color="blue">manufacturing</font> arrangements</td>
    </tr>
    <tr>
      <td>Certain <font color="blue">components</font> of our <font color="blue">products may</font> be available, at least initially,     <font color="blue">only from single sources</font></td>
    </tr>
    <tr>
      <td>There can be no assurance that we could find     <font color="blue">alternate suppliers</font> for any of these <font color="blue">components</font></td>
    </tr>
    <tr>
      <td>A delay of or <font color="blue">interruption</font>     in  production resulting from any <font color="blue">supply problem could</font> have a material     adverse effect on our business</td>
    </tr>
    <tr>
      <td>We rely on a small number of vendors and <font color="blue">contract <font color="blue">manufacture</font>rs</font> to supply us     with specialized equipment, tools and <font color="blue">components</font></td>
    </tr>
    <tr>
      <td>We rely on a small number of vendors and <font color="blue">contract <font color="blue">manufacture</font>rs</font> to     supply us with specialized equipment, tools and <font color="blue">components</font> for use in our     <font color="blue">development</font> and <font color="blue">manufacturing</font> processes</td>
    </tr>
    <tr>
      <td>There can be <font color="blue">no assurances</font> that     these <font color="blue">vendors will continue</font> to <font color="blue">supply us with <font color="blue">such specialized equipment</font></font>,     tools and <font color="blue">components</font>, nor can there be any assurances that we could find     <font color="blue">alternative</font> sources for <font color="blue">such specialized equipment</font> and tools</td>
    </tr>
    <tr>
      <td>A delay or     <font color="blue">interruption</font> in <font color="blue">development</font> or <font color="blue">manufacturing</font> resulting from our <font color="blue">inability</font> to     acquire the equipment, tools and <font color="blue">components</font> we need could have a material     adverse effect on our business</td>
    </tr>
    <tr>
      <td>We  depend  upon  <font color="blue">proprietary</font> <font color="blue">technology</font> and the status of patents and     <font color="blue">proprietary</font> <font color="blue">technology</font> is uncertain</td>
    </tr>
    <tr>
      <td>Our business and <font color="blue">competitive position</font> is <font color="blue">dependent upon</font> our ability to     protect our <font color="blue">proprietary</font> <font color="blue">technology</font> and <font color="blue">avoid infringing on</font> the <font color="blue">proprietary</font>     rights of others</td>
    </tr>
    <tr>
      <td>We have <font color="blue">conducted original research on</font> a number of aspects     relating to <font color="blue">pulmonary drug delivery</font></td>
    </tr>
    <tr>
      <td>While we <font color="blue">cannot assure</font> you that any of     our <font color="blue">patents will</font> provide a <font color="blue"><font color="blue">significant</font> commercial advantage</font>, these patents     are intended to <font color="blue">provide protection</font> for <font color="blue">important aspects</font> of our <font color="blue">technology</font>,     including methods for aerosol generation, devices used to <font color="blue">generate aerosols</font>,     breath control, compliance monitoring certain <font color="blue">pharmaceutical</font> formulations,     design of <font color="blue">dosage forms</font> and their <font color="blue">manufacturing</font>, and <font color="blue">testing methods</font></td>
    </tr>
    <tr>
      <td>In     addition, we are maintaining <font color="blue">as trade secrets</font> some of the <font color="blue">key elements</font> of     our  <font color="blue">manufacturing</font>  <font color="blue">technologies</font>;  <font color="blue">particularly</font>  those <font color="blue">associated with</font>     production of disposable unit-dose packets for the AERx system</td>
    </tr>
    <tr>
      <td>In <font color="blue">connection with</font> our <font color="blue">acquisition</font> of <font color="blue">assets from</font> the Weston Medical     Group in May 2003, we acquired certain <font color="blue">proprietary</font> <font color="blue">technologies</font> and other     <font color="blue">intellectual</font>  property relating to the <font color="blue">Intraject </font><font color="blue">subcutaneous delivery</font>     system</td>
    </tr>
    <tr>
      <td>While we have continued to develop the <font color="blue">technologies</font> relating to the     <font color="blue">Intraject </font>system, we <font color="blue">cannot assure</font> you that our efforts to protect the     <font color="blue">proprietary</font> <font color="blue">technologies</font> and other <font color="blue">intellectual</font> property that we have                                         24       _________________________________________________________________    [78]Table of <font color="blue">Contents       </font>acquired from <font color="blue">Weston Medical Group </font><font color="blue">will provide adequate protection</font> or     <font color="blue"><font color="blue">significant</font> commercial advantage</font></td>
    </tr>
    <tr>
      <td>To date we have been unable to secure a     partner for commercial-scale production of any <font color="blue">application</font> of the <font color="blue">Intraject </font>    system, and there can be no assurance that we will be able to <font color="blue">secure such</font> a     partner</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will depend</font> to a <font color="blue"><font color="blue">significant</font> extent on</font> our ability to     obtain and <font color="blue">enforce patents</font>, maintain <font color="blue">trade secret protection</font> and operate     <font color="blue">without infringing on</font> the <font color="blue"><font color="blue">proprietary</font> rights</font> of <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>Because the     field of needle-free drug delivery is crowded and a substantial number of     patents  have  been  issued and because <font color="blue">patent positions</font> can be highly     uncertain and <font color="blue">frequently involve complex legal</font> and factual questions, the     breadth of claims obtained in any <font color="blue">application</font> or the <font color="blue">enforceability</font> of our     <font color="blue">patents cannot</font> be predicted</td>
    </tr>
    <tr>
      <td><font color="blue">Commercialization </font>of <font color="blue">pharmaceutical</font> products     can also be subject to substantial delays as a result of the time required     for product <font color="blue">development</font>, testing and <font color="blue">regulatory</font> approval</td>
    </tr>
    <tr>
      <td>We also seek to protect some of these <font color="blue">inventions</font> through foreign     counterpart <font color="blue">application</font>s in selected other countries</td>
    </tr>
    <tr>
      <td><font color="blue">Statutory </font><font color="blue">differences</font>     in patentable subject matter may limit the protection we can obtain on some     of our <font color="blue"><font color="blue">inventions</font> outside</font> of the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>For example, methods of     <font color="blue">treating humans</font> are not patentable in many <font color="blue">countries outside</font> of the United     States</td>
    </tr>
    <tr>
      <td>These and other <font color="blue">issues may limit</font> the <font color="blue">patent protection</font> we will be     able to <font color="blue">secure outside</font> of the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>The coverage claimed in a patent <font color="blue">application</font> can be <font color="blue"><font color="blue">significant</font>ly</font>     reduced before a patent is issued, either in the <font color="blue">United States</font> or abroad</td>
    </tr>
    <tr>
      <td>Consequently, we do not know whether any of our pending or <font color="blue">future patent</font>     <font color="blue">application</font>s  will result in the issuance of patents or, to the extent     patents have been issued or will be issued, whether these <font color="blue">patents will</font> be     subjected  to  further  <font color="blue">proceedings limiting</font> their scope, will provide     <font color="blue">significant</font> <font color="blue">proprietary</font> protection or <font color="blue">competitive advantage</font>, or will be     <font color="blue">circumvented</font> or invalidated</td>
    </tr>
    <tr>
      <td>Furthermore, <font color="blue">patents already issued</font> to us or     our pending <font color="blue">application</font>s may become subject to dispute, and any disputes     could be <font color="blue">resolved against us</font></td>
    </tr>
    <tr>
      <td>For example, <font color="blue">Eli Lilly and Company </font>has brought     an <font color="blue">action against us seeking</font> to have one or more employees of <font color="blue">Eli Lilly     </font>named as co-inventors on one of our patents</td>
    </tr>
    <tr>
      <td>In addition, because patent <font color="blue">application</font>s in     the <font color="blue">United States</font> are currently maintained in <font color="blue">secrecy until patents issue</font>,     and  patent  <font color="blue">application</font>s in certain other <font color="blue">countries <font color="blue">generally</font></font> are not     <font color="blue">published until</font> more than 18 months after they are first filed, and because     <font color="blue">publication</font> of <font color="blue">discoveries</font> in scientific or <font color="blue">patent literature often lags</font>     behind actual <font color="blue">discoveries</font>, we cannot be certain that we were the first     creator of <font color="blue">inventions</font> <font color="blue">covered by</font> pending patent <font color="blue">application</font>s or that we were     the first to file patent <font color="blue">application</font>s on such <font color="blue">inventions</font></td>
    </tr>
    <tr>
      <td>Our policy is to require our officers, employees, <font color="blue">consultants</font> and     advisors to execute <font color="blue">proprietary</font> information and invention and <font color="blue">assignment</font>     <font color="blue"><font color="blue">agreement</font>s</font> upon commencement of their <font color="blue">relationships with us</font></td>
    </tr>
    <tr>
      <td>We cannot     assure  you,  however,  that  these <font color="blue"><font color="blue">agreement</font>s</font> will provide meaningful     protection  for  our  <font color="blue">inventions</font>,  trade  secrets or other <font color="blue">proprietary</font>     information  in  the  event  of <font color="blue">unauthorized use</font> or <font color="blue">disclosure</font> of such     information</td>
    </tr>
    <tr>
      <td>We also execute confidentiality <font color="blue"><font color="blue">agreement</font>s</font> with outside <font color="blue">collaborators</font>     and  <font color="blue">consultants</font></td>
    </tr>
    <tr>
      <td>However,  <font color="blue">disputes may</font> arise as to the ownership of     <font color="blue"><font color="blue">proprietary</font> rights</font> to the extent that outside <font color="blue">collaborators</font> or <font color="blue">consultants</font>     apply technological information developed <font color="blue">independently by them</font> or others to     our projects, or apply our <font color="blue">technology</font> to other projects, and we cannot     assure you that any <font color="blue">such disputes would</font> be resolved in our favor</td>
    </tr>
    <tr>
      <td>We may incur substantial costs if we are required to <font color="blue">defend ourselves</font>     in patent suits brought by <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">legal actions could seek</font>     damages and seek to enjoin testing, <font color="blue">manufacturing</font> and marketing of the     accused  product  or  process</td>
    </tr>
    <tr>
      <td>In addition to <font color="blue">potential <font color="blue">liability</font></font> for     <font color="blue"><font color="blue">significant</font> damages</font>, we could be required to obtain a license to continue to     <font color="blue">manufacture</font> or market the <font color="blue">accused product</font> or process and we <font color="blue">cannot assure</font>     you that any license required under any <font color="blue">such patent would</font> be made available     to us on acceptable terms, if at all</td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font>may also be <font color="blue">necessary</font> to     enforce our <font color="blue">patents against others</font> or to protect our know-how or trade     secrets</td>
    </tr>
    <tr>
      <td>Such <font color="blue">litigation</font> could result in substantial expense, and we cannot     assure you that any <font color="blue">litigation</font> would be resolved in our favor</td>
    </tr>
    <tr>
      <td><font color="blue">Sumatriptan </font>is <font color="blue">currently marketed under</font> the trade name Imitrex in     oral, nasal and injectable forms and the injectable form is <font color="blue">covered by</font> a     series of patents, the first of which is scheduled to <font color="blue">come off patent</font> in     2006  in  Europe and 2007 in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>There is an <font color="blue">additional</font>     US patent relating to the injectable form of sumatriptan that does not     expire  until 2009, though this patent has been challenged by multiple     parties and                                         25       _________________________________________________________________    [79]Table of <font color="blue">Contents       </font>may be invalidated</td>
    </tr>
    <tr>
      <td>There can be no assurance that this <font color="blue">patent will</font> be     invalidated, and if not, <font color="blue">under certain circumstances</font> we will be unable to     enter the US <font color="blue">market with</font> <font color="blue">Intraject </font>sumatriptan until 2009</td>
    </tr>
    <tr>
      <td>We may not obtain <font color="blue">regulatory</font> approval for our <font color="blue">products on</font> a <font color="blue">timely basis</font>, or     at all</td>
    </tr>
    <tr>
      <td>All <font color="blue">medical devices</font> and new drugs, including our <font color="blue">products under</font>     <font color="blue">development</font>, are subject to extensive and <font color="blue">rigorous regulation by</font> the federal     <font color="blue">government</font>, principally the FDA, and by state and local <font color="blue">government</font> agencies</td>
    </tr>
    <tr>
      <td>Such <font color="blue"><font color="blue">regulations</font> govern</font> the <font color="blue">development</font>, testing, <font color="blue">manufacture</font>, labeling,     storage, approval, advertising, promotion, sale and <font color="blue">distribution</font> of such     products</td>
    </tr>
    <tr>
      <td>Medical devices or <font color="blue">drug products</font> that are <font color="blue">marketed abroad</font> are also     subject to regulation by foreign <font color="blue">government</font>s</td>
    </tr>
    <tr>
      <td>The process for obtaining FDA approvals for <font color="blue">drug products</font> is <font color="blue">generally</font>     lengthy, expensive and uncertain</td>
    </tr>
    <tr>
      <td><font color="blue">Securing FDA </font>approvals often requires     <font color="blue">applicants</font> to submit extensive <font color="blue">clinical data</font> and supporting information to     the  FDA Even if granted, the FDA can <font color="blue">withdraw product clearances</font> and     approvals for failure to <font color="blue">comply with</font> <font color="blue">regulatory</font> <font color="blue">requirements</font> or upon the     occurrence of <font color="blue">unforeseen problems following initial marketing</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">activities</font> required before a <font color="blue">new drug product may</font> be marketed in     the <font color="blue">United States</font> include pre-clinical and <font color="blue">clinical testing</font> and submission     of a new drug <font color="blue">application</font> with the <font color="blue">FDA Preclinical </font>tests include <font color="blue">laboratory</font>     <font color="blue">evaluation</font> of <font color="blue">product chemistry</font> and other <font color="blue">characteristics</font> and <font color="blue">animal studies</font>     to assess the <font color="blue">potential safety</font> and efficacy of the <font color="blue">product as formulated</font></td>
    </tr>
    <tr>
      <td>Clinical <font color="blue">testing involves</font> the <font color="blue">administration</font> of the drug to <font color="blue">healthy human</font>     volunteers or to <font color="blue">patients under</font> the <font color="blue">supervision</font> of a <font color="blue">qualified principal</font>     investigator, usually a physician, pursuant to a FDA-reviewed protocol</td>
    </tr>
    <tr>
      <td>Human <font color="blue">clinical trials</font> typically are conducted in <font color="blue">three sequential</font>     phases, but the <font color="blue">phases may overlap</font></td>
    </tr>
    <tr>
      <td>Phase 1 trials consist of testing the     product in a small number of patients or normal volunteers, primarily for     safety, at one or more dosage levels, as well as characterization of a     drug’s pharmacokinetic and/or pharmacodynamic profile</td>
    </tr>
    <tr>
      <td>In Phase 2 clinical     trials,  in addition to safety, the efficacy of the product is usually     evaluated  in  a  <font color="blue">patient population</font></td>
    </tr>
    <tr>
      <td>Phase 3 trials typically involve     <font color="blue">additional</font>  testing  for  safety  and <font color="blue">clinical efficacy</font> in an expanded     <font color="blue">population at geographically disperse sites</font></td>
    </tr>
    <tr>
      <td>All of the phases of clinical     <font color="blue">studies must</font> be conducted in <font color="blue">conformance with</font> FDA’s <font color="blue">bioresearch monitoring</font>     <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>We  cannot  assure you that we will be able to obtain <font color="blue">necessary</font>     <font color="blue">regulatory</font> approvals on a <font color="blue">timely basis</font>, if at all, for any of our potential     products</td>
    </tr>
    <tr>
      <td>Even if granted, <font color="blue">regulatory</font> approvals may include <font color="blue">significant</font>     <font color="blue">limitation</font>s on the uses for which <font color="blue">products may</font> be marketed</td>
    </tr>
    <tr>
      <td>Moreover, we     <font color="blue">cannot assure</font> you that any required approvals, once obtained, will not be     withdrawn  or  that we will remain in <font color="blue">compliance with</font> other <font color="blue">regulatory</font>     <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>If we, or <font color="blue">manufacture</font>rs of our <font color="blue">components</font>, fail to <font color="blue">comply with</font>     applicable FDA and other <font color="blue">regulatory</font> <font color="blue">requirements</font>, we, and they, are subject     to sanctions, including:         •  <font color="blue">warning letters</font>;         •  fines;         •  <font color="blue">product recalls</font> or seizures;         •  <font color="blue">injunctions</font>;         •  refusals to <font color="blue">permit products</font> to be <font color="blue">imported into</font> or <font color="blue">exported out</font> of the     <font color="blue">United States</font>;         •  <font color="blue">withdrawals</font> of <font color="blue">previously</font> approved marketing <font color="blue">application</font>s; and         •  <font color="blue">criminal prosecutions</font></td>
    </tr>
    <tr>
      <td><font color="blue">Manufacturers </font>of drugs also are required to <font color="blue">comply with</font> the applicable     GMP <font color="blue">requirements</font>, which relate to product testing, quality assurance and     maintaining records and <font color="blue">documentation</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that we will be     able to <font color="blue">comply with</font> the applicable <font color="blue">GMP and other FDA </font><font color="blue">regulatory</font> <font color="blue">requirements</font>     for <font color="blue">manufacturing</font> as we expand our <font color="blue">manufacturing</font> <font color="blue">operations</font>, which would     impair our business</td>
    </tr>
    <tr>
      <td>In addition, to market our products in foreign <font color="blue">jurisdictions</font>, <font color="blue">Aradigm     </font>and our partners must obtain required <font color="blue">regulatory</font> approvals from foreign     <font color="blue">regulatory</font> agencies and <font color="blue">comply with</font> extensive <font color="blue">regulations</font> regarding safety     and quality</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that we will obtain <font color="blue">regulatory</font> approvals     in such                                         26       _________________________________________________________________    [80]Table of <font color="blue">Contents       </font><font color="blue">jurisdictions</font> or that we will not incur <font color="blue">significant</font> costs in obtaining or     maintaining any foreign <font color="blue">regulatory</font> approvals</td>
    </tr>
    <tr>
      <td>If approvals to market our     products are delayed, if we fail to receive these approvals, or if we lose     <font color="blue">previously</font> received approvals, our business would be impaired</td>
    </tr>
    <tr>
      <td>Because certain of our <font color="blue">clinical studies involve narcotics</font>, we are     <font color="blue">registered with</font> the DEA and our <font color="blue">facilities</font> are subject to inspection <font color="blue">and DEA     </font>export, import, security, and production quota <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>We cannot     assure you that we will not be required to incur <font color="blue">significant</font> costs to comply     with  DEA  <font color="blue">regulations</font> in the future or that such <font color="blue">regulations</font> will not     <font color="blue">otherwise harm</font> our business</td>
    </tr>
    <tr>
      <td>The results of preclinical and <font color="blue">clinical testing</font> are uncertain</td>
    </tr>
    <tr>
      <td>Before we can file for <font color="blue">regulatory</font> approval for the <font color="blue">commercial sale</font> of     our potential AERx and <font color="blue">Intraject </font>products, the FDA will require extensive     preclinical and <font color="blue">clinical testing</font> to <font color="blue">demonstrate</font> their safety and efficacy</td>
    </tr>
    <tr>
      <td>We have tested prototype patient-operated versions of our AERx and <font color="blue">Intraject </font>    <font color="blue"><font color="blue">delivery system</font>s</font> on a limited number of <font color="blue">individuals</font> in Phase 1 and Phase 2     <font color="blue">clinical trials</font> and have initiated a Phase 3 clinical trial for the AERx     iDMS If we do not or cannot complete <font color="blue">current trials</font> or progress to more     advanced <font color="blue">clinical trials</font>, we may not be able to <font color="blue">commercialize</font> our AERx or     <font color="blue">Intraject </font>products</td>
    </tr>
    <tr>
      <td><font color="blue">Completing </font><font color="blue">clinical trials</font> in a <font color="blue">timely manner</font> depends on, among other     factors, the <font color="blue">enrollment</font> of patients</td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">recruit patients depends</font>     on a number of factors, including the size of the <font color="blue">patient population</font>, the     proximity of patients to <font color="blue">clinical sites</font>, the <font color="blue">eligibility criteria</font> for the     study and the existence of competitive <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>Delays in planned     patient <font color="blue">enrollment</font> in our current or future <font color="blue">clinical trials</font> may result in     increased costs, program delays or both</td>
    </tr>
    <tr>
      <td>Although we believe the limited data we have regarding our potential     products is <font color="blue">encouraging</font>, the results of <font color="blue">initial preclinical</font> and clinical     testing  do  not <font color="blue">necessarily predict</font> the results that we will get from     subsequent or more extensive preclinical and <font color="blue">clinical testing</font></td>
    </tr>
    <tr>
      <td>Furthermore,     we <font color="blue">cannot assure</font> you that <font color="blue">clinical trials</font> of these <font color="blue">products will</font> <font color="blue">demonstrate</font>     that these products are safe and <font color="blue">effective</font> to the extent <font color="blue">necessary</font> to obtain     <font color="blue">regulatory</font> approvals</td>
    </tr>
    <tr>
      <td>Many companies in the <font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font>     <font color="blue">industries</font> have suffered <font color="blue">significant</font> setbacks in advanced <font color="blue">clinical trials</font>,     even after promising results in <font color="blue">earlier trials</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">cannot adequately</font>     <font color="blue">demonstrate</font> that any <font color="blue">therapeutic product</font> we are developing is safe and     <font color="blue">effective</font>,  <font color="blue">regulatory</font>  approval  of  that <font color="blue">product would</font> be delayed or     prevented, which would impair our business</td>
    </tr>
    <tr>
      <td>We are also developing <font color="blue">application</font>s of our delivery platforms for the     delivery of other compounds</td>
    </tr>
    <tr>
      <td>These <font color="blue">application</font>s are in <font color="blue">early stage</font>s of     <font color="blue">development</font> and we do not yet know the degree of testing and <font color="blue">development</font>     that will be needed to obtain <font color="blue">necessary</font> marketing approvals from the FDA and     other <font color="blue">regulatory</font> agencies</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that these <font color="blue">application</font>s will     prove  to be viable or that any <font color="blue">necessary</font> <font color="blue">regulatory</font> approvals will be     obtained in a <font color="blue">timely manner</font>, if at all</td>
    </tr>
    <tr>
      <td>In addition, the FDA may require us to provide <font color="blue">clinical data</font> beyond     what is currently planned to <font color="blue">demonstrate</font> that the chronic <font color="blue">administration</font> of     drugs delivered via the lung for systemic effect is safe</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font>     you that we will be able to <font color="blue">present such data</font> in a <font color="blue">timely manner</font>, or at all</td>
    </tr>
    <tr>
      <td>We  are in a <font color="blue">highly competitive market</font> and our <font color="blue">competitors</font> may develop     <font color="blue">alternative</font> therapies</td>
    </tr>
    <tr>
      <td>We are in competition with <font color="blue">pharmaceutical</font>, bio<font color="blue">technology</font> and drug     delivery companies, hospitals, research <font color="blue">organizations</font>, individual <font color="blue">scientists</font>     and <font color="blue">nonprofit <font color="blue">organizations</font></font> engaged in the <font color="blue">development</font> of <font color="blue">alternative</font> drug     <font color="blue"><font color="blue">delivery system</font>s</font> or <font color="blue">new drug research</font> and testing, as well as with entities     producing and developing <font color="blue"><font color="blue">injectable drug</font>s</font></td>
    </tr>
    <tr>
      <td>We are aware of a number of     <font color="blue">companies such as</font> Alkermes Pharmaceuticals, Inc</td>
    </tr>
    <tr>
      <td>and <font color="blue">Nektar Therapeutics     </font>(formerly Inhale Therapeutic Systems, Inc</td>
    </tr>
    <tr>
      <td>) that are <font color="blue">currently seeking</font> to     develop  <font color="blue">new products</font> and non-invasive <font color="blue">alternative</font>s to <font color="blue">injectable drug</font>     delivery, including oral <font color="blue"><font color="blue">delivery system</font>s</font>, intranasal <font color="blue"><font color="blue">delivery system</font>s</font>,     transdermal systems, buccal and <font color="blue">colonic absorption systems</font></td>
    </tr>
    <tr>
      <td>Many of these companies and entities have     greater research and <font color="blue">development</font> <font color="blue">capabilities</font>, experience, <font color="blue">manufacturing</font>,     marketing, financial and managerial resources than we do and many of these     companies may have <font color="blue">application</font>s for their delivery platforms that are in a     more <font color="blue">advanced stage</font> of                                         27       _________________________________________________________________    [81]Table of <font color="blue">Contents       </font><font color="blue">development</font> than our <font color="blue">application</font>s</td>
    </tr>
    <tr>
      <td>Accordingly, our <font color="blue">competitors</font> may succeed     in developing competing <font color="blue">technologies</font>, obtaining FDA approval for products or     gaining market <font color="blue">acceptance</font> more <font color="blue">rapidly than</font> we can</td>
    </tr>
    <tr>
      <td>We <font color="blue"><font color="blue">depend on</font> key personnel</font> and <font color="blue">must continue</font> to attract and retain key     employees</td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on</font> a small number of key <font color="blue">management</font> and <font color="blue">technical personnel</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success also depends on</font> our ability to attract and retain <font color="blue">additional</font>     highly qualified marketing, <font color="blue">management</font>, <font color="blue">manufacturing</font>, <font color="blue">engineering</font> and     research and <font color="blue">development</font> personnel</td>
    </tr>
    <tr>
      <td>We <font color="blue">face intense competition</font> in our     recruiting <font color="blue">activities</font> and may not be able to attract or retain qualified     personnel</td>
    </tr>
    <tr>
      <td>Losing any of these <font color="blue">key employees could harm</font> our business and     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We may be exposed to <font color="blue">product <font color="blue">liability</font></font></td>
    </tr>
    <tr>
      <td>Researching, developing and <font color="blue">commercializing</font> <font color="blue">medical devices</font> and     <font color="blue">therapeutic product</font>s entail <font color="blue">significant</font> <font color="blue">product <font color="blue">liability</font></font> risks</td>
    </tr>
    <tr>
      <td>The use of     our products in <font color="blue">clinical trials</font> and the <font color="blue">commercial sale</font> of such <font color="blue">products may</font>     expose  us to <font color="blue">liability</font> claims</td>
    </tr>
    <tr>
      <td>These claims might be made <font color="blue">directly by</font>     consumers or by <font color="blue">pharmaceutical</font> companies or <font color="blue">others selling such products</font></td>
    </tr>
    <tr>
      <td><font color="blue">Companies </font>often address the exposure of <font color="blue">such risk by</font> obtaining product     <font color="blue">liability</font> insurance</td>
    </tr>
    <tr>
      <td>Although we currently have <font color="blue">product <font color="blue">liability</font></font> insurance,     there can be no assurance that we can maintain <font color="blue">such insurance</font> or obtain     <font color="blue">additional</font> insurance on acceptable terms, in <font color="blue">amounts sufficient</font> to protect     our business, or at all</td>
    </tr>
    <tr>
      <td>A successful claim <font color="blue">brought against us</font> in excess of     our <font color="blue">insurance coverage would</font> have a material adverse effect on our business</td>
    </tr>
    <tr>
      <td>Third-party <font color="blue">reimbursement</font> for our products is uncertain</td>
    </tr>
    <tr>
      <td>In <font color="blue">both domestic</font> and foreign markets, sales of our <font color="blue">potential products</font>     depend in part on the <font color="blue">availability</font> of <font color="blue">reimbursement</font> from third-party payers     such  as  <font color="blue">government</font> health <font color="blue">administration</font> authorities, private health     insurers and other <font color="blue">organizations</font></td>
    </tr>
    <tr>
      <td>Third-party <font color="blue">payers often challenge</font> the     price and cost-<font color="blue">effective</font>ness of <font color="blue">medical products</font> and services</td>
    </tr>
    <tr>
      <td><font color="blue">Significant     </font><font color="blue">uncertainty</font> exists as to the <font color="blue">reimbursement</font> status of <font color="blue">newly approved health</font>     care  products</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that any of our <font color="blue">products will</font> be     reimbursable by third-party payers</td>
    </tr>
    <tr>
      <td>In addition, we <font color="blue">cannot assure</font> you that     our <font color="blue">products will</font> be considered cost-<font color="blue">effective</font> or that adequate third-party     <font color="blue">reimbursement</font>  will be available to <font color="blue">enable us</font> to maintain <font color="blue">price levels</font>     sufficient to realize a profit</td>
    </tr>
    <tr>
      <td><font color="blue">Legislation </font>and <font color="blue">regulations</font> <font color="blue">affecting</font> the     pricing of <font color="blue">pharmaceutical</font>s may change before our products are approved for     marketing and any such changes could further limit <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">use <font color="blue">hazardous</font> materials</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">operations</font> involve use of <font color="blue">hazardous</font> and toxic materials, chemicals     and  various  <font color="blue">radioactive compounds</font> that generate <font color="blue">hazardous</font>, toxic and     <font color="blue">radioactive wastes</font></td>
    </tr>
    <tr>
      <td>Although we believe that our <font color="blue">safety procedures</font> for     handling and disposing of such materials <font color="blue">comply with</font> all state and federal     <font color="blue">regulations</font>  and standards, we <font color="blue">cannot completely eliminate</font> the risk of     <font color="blue"><font color="blue">accident</font>al contamination</font> or <font color="blue">injury from</font> these materials</td>
    </tr>
    <tr>
      <td>In the event of     such an <font color="blue">accident</font>, we could be held liable for any damages that result and     such <font color="blue">liability</font> could exceed the resources of our business</td>
    </tr>
    <tr>
      <td>Our stock price is likely to <font color="blue">remain volatile</font></td>
    </tr>
    <tr>
      <td>The  <font color="blue">market prices</font> for securities of many companies in the drug     <font color="blue">delivery industry</font>, including ours, have <font color="blue">historically been highly volatile</font>,     and the <font color="blue">market from</font> time to time has experienced <font color="blue">significant</font> price and     <font color="blue">volume <font color="blue">fluctuations</font> unrelated</font> to the operating performance of particular     companies</td>
    </tr>
    <tr>
      <td>Prices for our <font color="blue">common stock</font> may be influenced by many factors,     including:         •  investor <font color="blue">perception</font> of us;         •  analyst <font color="blue">recommendations</font>;         •  <font color="blue">fluctuations</font> in our operating results;                                         28       _________________________________________________________________    [82]Table of <font color="blue">Contents       </font>  •  <font color="blue">market conditions</font> relating to the drug <font color="blue">delivery industry</font>;         •  <font color="blue">announcements</font> of <font color="blue">technological innovations</font> or <font color="blue">new commercial products</font>     by us or our <font color="blue">competitors</font>;          •  publicity regarding actual or potential <font color="blue">development</font>s relating to     <font color="blue">products under</font> <font color="blue">development</font> by us or our <font color="blue">competitors</font>;         •  failure to establish new <font color="blue">collaborative</font> relationships;         •  <font color="blue">development</font>s or <font color="blue">disputes concerning patent</font> or <font color="blue"><font color="blue">proprietary</font> rights</font>;         •  delays in the <font color="blue">development</font> or approval of our <font color="blue">product candidates</font>;          •   <font color="blue">regulatory</font>  <font color="blue">development</font>s  in both the <font color="blue">United States</font> and foreign     countries;         •  public concern as to the safety of drug delivery <font color="blue">technologies</font>;         •  period-to-period <font color="blue">fluctuations</font> in financial results;         •  <font color="blue">future sales</font> of substantial amounts of <font color="blue">common stock</font> by <font color="blue">shareholders</font>; or         •  economic and other <font color="blue">external factors</font></td>
    </tr>
    <tr>
      <td>In  the past, class action securities <font color="blue">litigation</font> has often been     instituted against companies following periods of <font color="blue">volatility</font> in the market     price of their securities</td>
    </tr>
    <tr>
      <td>Any such <font color="blue">litigation</font> instigated against us could     result in substantial costs and a diversion of <font color="blue">management</font>’s attention and     resources</td>
    </tr>
    <tr>
      <td>We have implemented certain anti-takeover provisions</td>
    </tr>
    <tr>
      <td>Certain provisions of our articles of <font color="blue">incorporation</font> and the California     General Corporation Law <font color="blue">could discourage</font> a <font color="blue">third party</font> from acquiring, or     make it more <font color="blue">difficult</font> for a <font color="blue">third party</font> to acquire, control of our company     <font color="blue">without approval</font> of our board of <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">provisions could also</font>     limit the price that <font color="blue">certain investors might</font> be willing to pay in the future     for  shares of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Certain <font color="blue">provisions allow</font> the board of     <font color="blue">directors</font> to authorize the issuance of <font color="blue">preferred stock with rights</font> superior     to those of the <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We are also subject to the provisions of     Section 1203 of the <font color="blue">California General Corporation Law </font>which requires a     <font color="blue">fairness opinion</font> to be provided to our <font color="blue">shareholders</font> in <font color="blue">connection with</font> their     <font color="blue">consideration</font> of any proposed “interested party” reorganization transaction</td>
    </tr>
    <tr>
      <td>We have adopted a <font color="blue">shareholder rights</font> plan, <font color="blue">commonly known as</font> a “poison     pill”</td>
    </tr>
    <tr>
      <td>We have <font color="blue">also adopted</font> an Executive Officer Severance Plan and a Form     of Change of Control Agreement, both of <font color="blue">which may provide</font> for the payment of     benefits to our officers in <font color="blue">connection with</font> an <font color="blue">acquisition</font></td>
    </tr>
    <tr>
      <td>The provisions     described above, our <font color="blue">poison pill</font>, our severance plan and our change of     control <font color="blue"><font color="blue">agreement</font>s</font>, and provisions of the <font color="blue">California General Corporation Law </font>    may discourage, delay or prevent a <font color="blue">third party</font> from acquiring us</td>
    </tr>
  </tbody>
</table>